Should I buy or sell Protalix BioTherapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Protalix BioTherapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PLX shares. View PLX analyst ratings or view top-rated stocks .

What is Protalix BioTherapeutics' stock price target for 2024?

1 Wall Street research analysts have issued 12 month price objectives for Protalix BioTherapeutics' stock. Their PLX share price targets range from $10.00 to $10.00. On average, they expect the company's share price to reach $10.00 in the next year. This suggests a possible upside of 584.9% from the stock's current price. View analysts price targets for PLX or view top-rated stocks among Wall Street analysts .

How have PLX shares performed in 2023?

Protalix BioTherapeutics' stock was trading at $1.37 at the start of the year. Since then, PLX shares have increased by 6.6% and is now trading at $1.46. View the best growth stocks for 2023 here .

How were Protalix BioTherapeutics' earnings last quarter?

Protalix BioTherapeutics, Inc. (NYSE:PLX) posted its quarterly earnings data on Monday, November, 6th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.03. The company had revenue of $10.35 million for the quarter, compared to the consensus estimate of $7.64 million. Protalix BioTherapeutics had a trailing twelve-month return on equity of 62.80% and a net margin of 16.68%. During the same quarter last year, the firm posted ($0.11) earnings per share.

When did Protalix BioTherapeutics' stock split?

Protalix BioTherapeutics shares reverse split on the morning of Friday, December 20th 2019. The 1-10 reverse split was announced on Monday, December 9th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 19th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Protalix BioTherapeutics' major shareholders?

Protalix BioTherapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include GSA Capital Partners LLP (0.69%), Northern Trust Corp (0.57%), Connor Clark & Lunn Investment Management Ltd. (0.23%), Bank of New York Mellon Corp (0.23%), Charles Schwab Investment Management Inc. (0.21%) and Allspring Global Investments Holdings LLC (0.19%). Insiders that own company stock include Aharon Schwartz, Dror Bashan and Pharma Technologies Ltd Dexcel. View institutional ownership trends .

How do I buy shares of Protalix BioTherapeutics?

Shares of PLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Protalix BioTherapeutics Stock Price, News & Analysis (NYSE:PLX)

$1.46

-0.05 (-3.31%)

(As of 12/1/2023 ET)

Compare

Today's Range: $1.46
▼
$1.52
50-Day Range: $1.34
▼
$2.28
52-Week Range: $1.09
▼
$3.55

Volume: 230,262 shs
Average Volume: 477,352 shs
Market Capitalization: $104.51 million

P/E Ratio: 29.21
Dividend Yield: N/A
Price Target: $10.00

Protalix BioTherapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 584.9% Upside
$10.00 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$90,322 Bought Last Quarter
Proj. Earnings Growth: 40.00%
From $0.10 to $0.14 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Medical Sector

297th out of 953 stocks

Biological Products, Except Diagnostic Industry

46th out of 156 stocks

3.5

Analyst's Opinion

Consensus Rating
Protalix BioTherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.00, Protalix BioTherapeutics has a forecasted upside of 584.9% from its current price of $1.46.
Amount of Analyst Coverage
Protalix BioTherapeutics has only been the subject of 1 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for PLX.

0.0

Dividend Strength

Dividend Yield
Protalix BioTherapeutics does not currently pay a dividend.
Dividend Growth
Protalix BioTherapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PLX.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Protalix BioTherapeutics this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for PLX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Protalix BioTherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $90,322.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 4.97% of the stock of Protalix BioTherapeutics is held by insiders.
Percentage Held by Institutions
Only 12.51% of the stock of Protalix BioTherapeutics is held by institutions.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Protalix BioTherapeutics are expected to grow by 40.00% in the coming year, from $0.10 to $0.14 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Protalix BioTherapeutics is 29.21, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 111.94.
Price to Earnings Ratio vs. Sector
The P/E ratio of Protalix BioTherapeutics is 29.21, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 108.20.
Price to Book Value per Share Ratio
Protalix BioTherapeutics has a P/B Ratio of 2.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Protalix BioTherapeutics Stock (NYSE:PLX)

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is based in Hackensack, New Jersey. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

PLX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PLX Stock News Headlines

December 3, 2023 | americanbankingnews.com

Protalix BioTherapeutics (NYSE:PLX) Upgraded at StockNews.com

November 7, 2023 | finance.yahoo.com

PLX: More Regulatory Approvals

December 3, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 7, 2023 | finance.yahoo.com

Protalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2023 Earnings Call Transcript

November 6, 2023 | msn.com

American Well, Protalix BioTherapeutics among healthcare movers

November 6, 2023 | msn.com

Protalix BioTherapeutics GAAP EPS of -$0.04 beats by $0.03, revenue of $10.35M beats by $2.71M

November 6, 2023 | washingtonpost.com

Protalix: Q3 Earnings Snapshot

November 6, 2023 | markets.businessinsider.com

Protalix BioTherapeutics Inc. Q3 loss drops in line with estimates

December 3, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 6, 2023 | finance.yahoo.com

Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results

November 6, 2023 | finance.yahoo.com

Protalix BioTherapeutics Inc (PLX) Reports Q3 2023 Financial Results

November 3, 2023 | msn.com

Protalix BioTherapeutics Q3 Earnings Preview

October 31, 2023 | theglobeandmail.com

Upcoming Earnings Release Paired With Price Target Raise Sends Stock Soaring

October 30, 2023 | finance.yahoo.com

Protalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023

October 20, 2023 | msn.com

Palatin Technologies, Protalix BioTherapeutics, Arcutis among healthcare movers

October 9, 2023 | finance.yahoo.com

Protalix BioTherapeutics Issues Statement Regarding Security Situation in Israel

September 12, 2023 | markets.businessinsider.com

Protalix BioTherapeutics Appoints Eliot Richard Forster To Succeed Zeev Bronfeld As Chairman

September 12, 2023 | finance.yahoo.com

Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors

September 6, 2023 | msn.com

Protalix BioTherapeutics Stock Is A Hold Pending Successful Commercialization Of Elfabrio

September 6, 2023 | finance.yahoo.com

Protalix BioTherapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 8, 2023 | msn.com

PLX: Second Quarter Results

August 8, 2023 | seekingalpha.com

Protalix BioTherapeutics beats Q2 top and bottom line estimates

August 8, 2023 | finance.yahoo.com

Protalix BioTherapeutics, Inc. (AMEX:PLX) Q2 2023 Earnings Call Transcript

August 7, 2023 | finance.yahoo.com

Protalix BioTherapeutics Reports Second Quarter 2023 Financial and Business Results

August 6, 2023 | markets.businessinsider.com

Here's what Wall Street expects from Protalix BioTherapeutics's earnings

August 4, 2023 | benzinga.com

Preview: Protalix BioTherapeutics's Earnings

August 1, 2023 | finance.yahoo.com

Protalix BioTherapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

See More Headlines

Receive PLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protalix BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/06/2023
Today: 12/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:PLX
CUSIP: N/A
CIK: 1006281
Web: www.protalix.com
Phone: 201-696-9345
Fax: 972-4988-9489
Employees: 193
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $10.00
High Stock Price Target: $10.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +584.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.05
Trailing P/E Ratio: 29.21
Forward P/E Ratio: 14.60
P/E Growth: N/A
Net Income: $-14,930,000.00
Net Margins: 16.68%
Pretax Margin: 18.52%
Return on Equity: 62.80%
Return on Assets: 14.23%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.67
Quick Ratio: 1.18

Sales & Book Value

Annual Sales: $47.64 million
Price / Sales: 2.19
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.53 per share
Price / Book: 2.75

Miscellaneous

Outstanding Shares: 71,580,000
Free Float: 68,023,000
Market Cap: $104.51 million
Optionable: Optionable
Beta: 1.17

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. Dror Bashan (Age 56)
President, CEO & Director
Comp: $473.16k
Mr. Eyal Rubin M.B.A. (Age 47)
Senior VP, CFO, Treasurer & Corporate Secretary
Comp: $813.73k
Mr. Yaron Naos (Age 59)
Senior Vice President of Operations
Comp: $409.95k
Ms. Yael Fellous
Vice President of Human Resources

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PLX Stock Analysis - Frequently Asked Questions

Should I buy or sell Protalix BioTherapeutics stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Protalix BioTherapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PLX shares.
View PLX analyst ratings or view top-rated stocks.
What is Protalix BioTherapeutics' stock price target for 2024?: 1 Wall Street research analysts have issued 12 month price objectives for Protalix BioTherapeutics' stock. Their PLX share price targets range from $10.00 to $10.00. On average, they expect the company's share price to reach $10.00 in the next year. This suggests a possible upside of 584.9% from the stock's current price.
View analysts price targets for PLX or view top-rated stocks among Wall Street analysts.
How have PLX shares performed in 2023?: Protalix BioTherapeutics' stock was trading at $1.37 at the start of the year. Since then, PLX shares have increased by 6.6% and is now trading at $1.46.
View the best growth stocks for 2023 here.
How were Protalix BioTherapeutics' earnings last quarter?: Protalix BioTherapeutics, Inc. (NYSE:PLX) posted its quarterly earnings data on Monday, November, 6th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.03. The company had revenue of $10.35 million for the quarter, compared to the consensus estimate of $7.64 million. Protalix BioTherapeutics had a trailing twelve-month return on equity of 62.80% and a net margin of 16.68%. During the same quarter last year, the firm posted ($0.11) earnings per share.

When did Protalix BioTherapeutics' stock split?: Protalix BioTherapeutics shares reverse split on the morning of Friday, December 20th 2019. The 1-10 reverse split was announced on Monday, December 9th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 19th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
Who are Protalix BioTherapeutics' major shareholders?: Protalix BioTherapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include GSA Capital Partners LLP (0.69%), Northern Trust Corp (0.57%), Connor Clark & Lunn Investment Management Ltd. (0.23%), Bank of New York Mellon Corp (0.23%), Charles Schwab Investment Management Inc. (0.21%) and Allspring Global Investments Holdings LLC (0.19%). Insiders that own company stock include Aharon Schwartz, Dror Bashan and Pharma Technologies Ltd Dexcel.
View institutional ownership trends.
How do I buy shares of Protalix BioTherapeutics?: Shares of PLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:PLX) was last updated on 12/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Protalix BioTherapeutics Stock Price, News & Analysis (NYSE:PLX)

Protalix BioTherapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Protalix BioTherapeutics Stock (NYSE:PLX)

PLX Stock Price History

PLX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

PLX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™